von Willebrand Disease in Pediatrics: Evaluation and Management

Sarah H. O'Brien, Surbhi Saini

Research output: Contribution to journalReview article

Abstract

Advances in the use of standardized bleeding assessment tools, functional laboratory assays, and genetic testing have all improved the ability of hematologists to more accurately diagnose von Willebrand disease (VWD) in patients presenting with easy bruising or bleeding. This article reviews these recent advances, as well as currently available treatment options, including desmopressin, antifibrinolytics, and both plasma-based and recombinant von Willebrand factor products. The diagnosis of VWD remains complex and this article provides an understanding of the various subtypes and phenotypes of VWD, as well as the appropriateness and interpretation of the many available laboratory tests.

Original languageEnglish (US)
Pages (from-to)425-438
Number of pages14
JournalHematology/Oncology Clinics of North America
Volume33
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

von Willebrand Diseases
Pediatrics
Hemorrhage
Deamino Arginine Vasopressin
Antifibrinolytic Agents
von Willebrand Factor
Genetic Testing
Phenotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

O'Brien, Sarah H. ; Saini, Surbhi. / von Willebrand Disease in Pediatrics : Evaluation and Management. In: Hematology/Oncology Clinics of North America. 2019 ; Vol. 33, No. 3. pp. 425-438.
@article{0ba8db72aaaa496ea8f2c6226b2d1e8a,
title = "von Willebrand Disease in Pediatrics: Evaluation and Management",
abstract = "Advances in the use of standardized bleeding assessment tools, functional laboratory assays, and genetic testing have all improved the ability of hematologists to more accurately diagnose von Willebrand disease (VWD) in patients presenting with easy bruising or bleeding. This article reviews these recent advances, as well as currently available treatment options, including desmopressin, antifibrinolytics, and both plasma-based and recombinant von Willebrand factor products. The diagnosis of VWD remains complex and this article provides an understanding of the various subtypes and phenotypes of VWD, as well as the appropriateness and interpretation of the many available laboratory tests.",
author = "O'Brien, {Sarah H.} and Surbhi Saini",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.hoc.2019.01.010",
language = "English (US)",
volume = "33",
pages = "425--438",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

von Willebrand Disease in Pediatrics : Evaluation and Management. / O'Brien, Sarah H.; Saini, Surbhi.

In: Hematology/Oncology Clinics of North America, Vol. 33, No. 3, 01.06.2019, p. 425-438.

Research output: Contribution to journalReview article

TY - JOUR

T1 - von Willebrand Disease in Pediatrics

T2 - Evaluation and Management

AU - O'Brien, Sarah H.

AU - Saini, Surbhi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Advances in the use of standardized bleeding assessment tools, functional laboratory assays, and genetic testing have all improved the ability of hematologists to more accurately diagnose von Willebrand disease (VWD) in patients presenting with easy bruising or bleeding. This article reviews these recent advances, as well as currently available treatment options, including desmopressin, antifibrinolytics, and both plasma-based and recombinant von Willebrand factor products. The diagnosis of VWD remains complex and this article provides an understanding of the various subtypes and phenotypes of VWD, as well as the appropriateness and interpretation of the many available laboratory tests.

AB - Advances in the use of standardized bleeding assessment tools, functional laboratory assays, and genetic testing have all improved the ability of hematologists to more accurately diagnose von Willebrand disease (VWD) in patients presenting with easy bruising or bleeding. This article reviews these recent advances, as well as currently available treatment options, including desmopressin, antifibrinolytics, and both plasma-based and recombinant von Willebrand factor products. The diagnosis of VWD remains complex and this article provides an understanding of the various subtypes and phenotypes of VWD, as well as the appropriateness and interpretation of the many available laboratory tests.

UR - http://www.scopus.com/inward/record.url?scp=85064703347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064703347&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2019.01.010

DO - 10.1016/j.hoc.2019.01.010

M3 - Review article

C2 - 31030811

AN - SCOPUS:85064703347

VL - 33

SP - 425

EP - 438

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -